Academic Collaboration Opportunity Leverage FluoroPharma's ties with Massachusetts General Hospital and Harvard Medical School to explore co-development, licensing, or joint ventures in novel PET imaging agents for CAD and atherosclerosis. Target translational research programs and research institutes as gateways to commercialization and early adoption.

Outsourcing for Milestones With a small team, the company will likely rely on external partners for GMP manufacturing, clinical trials, and regulatory affairs. Position as a CRO/CMO partner offering radiopharmaceutical synthesis, quality control, and regulatory documentation to accelerate development milestones and reduce time to market.

Cardiovascular Imaging Demand Focus go-to-market on hospitals, imaging centers, and distributors expanding PET capacity to detect CAD and vascular inflammation. Offer licensing, distribution, or co-development deals for the PET agents, leveraging integration with existing imaging workflows.

Strategic Funding Pathways The modest funding level suggests opportunities to partner with venture funds, government grants, or pharma co-development agreements. Propose milestone-based collaborations tied to clinical validation and regulatory approvals to secure funding alongside partner investments.

Competitive Differentiation Highlight the unique platform developed with leading researchers and the initial CAD imaging focus, plus detection of inflamed plaques. Position FluoroPharma as a differentiated supplier for imaging agents to large OEMs or academic networks seeking novel PET tracers.